Get ready to move over, Sanofi. A slew of Big Pharma rivals are reportedly weighing their own bids for buyout target Medivation.
Novartis, Pfizer and AstraZeneca are all exploring pitching a counteroffer for the San Francisco drugmaker, which Friday rejected a $9.3 billion buyout bid from the French pharma giant, Bloomberg reports. The trio is conferring with advisers about Medivation’s value, and whether and how to move forward, though there’s no guarantee they’ll come through with their own proposals.
Astellas, which markets star Medivation cancer drug Xtandi, could also jump into the mix, analysts have predicted.
Of course, Sanofi–which saw its $52.50-per-share bid snubbed–could always raise its offer. Still, despite its desire to boost its oncology portfolio, the French drugmaker is wary of overpaying, Bloomberg’s sources say. Medivation–which said the bid substantially undervalued its business–is looking for bids of at least $65 per share, the news service reports, and analysts including Leerink Partners’ Geoffrey Porges and Canaccord Genuity’s David Evanson have estimated value as high as $70.
It’s no surprise multiple drugmakers are giving Medivation a look, considering how many companies have stated a desire to expand in oncology. After last year snagging GlaxoSmithKline’s cancer drugs in a multibillion-dollar asset swap, Novartis has a big focus on the field, and Pfizer could once again be looking to bulk up its three operating units in the wake of its canceled deal with Allergan.
Meanwhile, AstraZeneca has been looking to the cancer arena to help spark the revenue turnaround CEO Pascal Soriot has been promising.
Xtandi could help any of them toward achieving their goals. The prostate cancer therapy’s sales–shared with Astellas–rang up at $1.9 billion worldwide last year, and analysts predict the med will eventually overtake first-to-market competitor pill Zytiga from Johnson & Johnson.
By Carly Helfand
Source: Fierce Pharma
Despite atherosclerotic cardiovascular disease (ASCVD) being the leading cause of death for people with Type 2 diabetes, half of those people have no idea of this risk. Novo Nordisk has teamed up with the Preventive Cardiovascular Nurses Association (PCNA) for “Making the Connection,” a program to help increase understanding of the link between the two diseases.
The first ever treatment for broken heart syndrome – also known as Takotsubo cardiomyopathy – is to be trialled by researchers at the University of Aberdeen. Scientists will trial a programme of exercise conditioning and psychological therapy for people who have been diagnosed with the condition following a £300,000 grant from the British Heart Foundation.
Nestlé Health Science is set to acquire The Better Health Company (TBHC), as part of its goals to grow global market share while spurring innovation across the nutrition industry. The acquisition includes the GO Healthy brand with its vitamins and supplements, Egmont, the Manuka honey brand and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins minerals and supplements.
